ristocetin


Also found in: Medical, Wikipedia.
Translations

ris·to·ce·tin

n. ristocetina, antibiótico que se usa en el tratamiento de infecciones producidas por un estreptococo gram-positivo.
References in periodicals archive ?
Whole blood count, peripheral blood smear, blood group, ferritin, platelet function analyzer 100 (PFA-100), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), fibrinogen, von Willebrand factor antigen (VWF:Ag), VWF ristocetin cofactor (VWF:RCo), factor VIII (F Viii), and platelet aggregation assays were performed.
Bernard-Soulier syndrome lacks a platelet response only for ristocetin and is associated with thrombocytopenia and giant platelets.
For patients undergoing major surgery, the goal of therapy is to treat with DDAVP or FVIII concentrates to maintain ristocetin cofactor levels between 50-100% for a period of 3-10 days and if the patient undergoes a percutaneous procedure, the length of treatment is shorter (18).
Hemostasis Testing System, includes HemosIL AcuStar VWF Antigen (VWF:Ag) and HemosIL AcuStar VWF Ristocetin Cofactor (VWF:RCo) Activity assays.
In platelet agregometer test, GT platelets do not aggregate following interaction with any substance except for ristocetin.
Normal platelet aggregation is noted with exposure to ADP, collagen, epinephrine, and arachidonic acid, but aggregation is characteristically absent with the addition of ristocetin or botrecetin, and the PFA-100 test is abnormal, as seen in Figure 1.
The vWF:RCo assay measures plasma vWF by testing the ability of vWF to induce platelet agglutination in the presence of the antibiotic ristocetin (3).
The response to the following agonists are now routinely assessed by LTA in our laboratory: (a) ristocetin (Catalogue number 5199; 15mg/ml; Helena Laboratories, Melbourne Australia), used at two or more concentrations to assess minimum and maximum thresholds (typically over the range 0.
A marked elevation in von Willebrand factor antigen (factor VIII:Ag), an elevation in ristocetin cofactor (VIII:RcoF) (Rossi et al 1980) and a slight elevation in factor VIII:C, has been observed to occur prior to the development of DVT (Myllenen et al 1987, Rossi et al 1980).
Results of assays for von Willebrand's disease were normal, including ristocetin cofactor (174%), factor VIII assay (208 U/dL), and von Willebrand's antigen (185 U/dL).
The prothrombin time, partial thromboplastin time, plasma fibrinogen concentration, von Willebrand factor antigen concentration, Factor VIII activity, and ristocetin cofactor activity were all normal.
Studies in vitro showed that platelet aggregation responses induced by ristocetin and botrocetin and the binding kinetics of VWF to both GPIb[alpha] isoforms ([Met.